Step 3 Semaglutide: Reaching 1.0 mg on the Wegovy Dose Ladder

Why the titration schedule is designed the way it is

Wegovy's dose ladder (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg (and now 7.2 mg for eligible patients)) isn't arbitrary. Each step is held for approximately four weeks to let the body adapt to semaglutide's effects on gastric emptying and appetite signalling before the dose rises again. Step 3 at 1.0 mg sits at the midpoint of that journey: beyond the introductory doses but still below the therapeutic maintenance level for most people.

The logic matters because gut-related side effects (nausea, loose stools, burping, that full-before-you've-started feeling) are most pronounced after a dose increase, then usually settle within a week or two. Spending a full four weeks at each step gives those effects time to pass before the next increase lands. If they haven't settled by the time a step-up would normally be due, staying put for an extra month is a legitimate and common clinical choice. That's not a setback; it's the titration working as intended. You can read more about how the full dose schedule is structured on our semaglutide dose steps overview.

A question our prescribers hear most weeks is whether a person can move through the steps faster if they feel fine. The honest answer is that the schedule is built on the clinical trial data, and compressing it increases GI risk without clear benefit to long-term weight outcomes. Patience here is pharmacology, not bureaucracy.

What tends to change (and what doesn't) between step 2 and step 3

At step 2 (0.5 mg) appetite suppression becomes noticeable for many people, though the effect can feel inconsistent across the week. By 1.0 mg the GLP-1 receptor engagement is stronger, and most people report appetite reduction that feels more stable day-to-day rather than peaking around the injection day and fading.

Weight change at step 3 varies considerably. Some people see their most significant early losses here; others find the most change comes after reaching the 1.7 mg or 2.4 mg maintenance dose. Neither pattern indicates something is wrong. What the STEP 1 trial, which we cover in more detail on our semaglutide step 1 page (published in the New England Journal of Medicine) showed was an average weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose, with most of that change accumulating over the full trial period rather than front-loading in the early steps.

Side effects at 1.0 mg are similar in character to earlier steps but can feel more noticeable if the body hasn't fully adjusted to 0.5 mg. Nausea is the most commonly reported. Eating smaller portions, avoiding fatty or very rich food, and staying well hydrated all reduce the likelihood of GI discomfort. If you have questions about specific foods, our page on eating cheese while taking Wegovy is a useful example of the kind of dietary guidance we provide. If symptoms are persistent or severe, contact your prescriber rather than pushing through.

The decision to move to step 4, or to stay at 1.0 mg

After four weeks at 1.0 mg the standard clinical pathway moves to 1.7 mg. Whether that happens on schedule depends on how well the current dose is being tolerated. If nausea or vomiting is still pronounced, a prescriber may recommend extending the time at 1.0 mg. If everything has settled and appetite control feels manageable, moving up is usually appropriate.

It's worth knowing that 1.0 mg is not a maintenance dose under the Wegovy licence, it's an intermediate step. Staying here long-term isn't the plan; the licence and the trial data are built around 2.4 mg (and now 7.2 mg as an option approved by the MHRA in early 2026) as the target. The step 5 dose at 1.7 mg and then the maintenance level are where clinical guidance expects most people to land. Details of what Wegovy treatment costs privately are set out clearly on our pricing page, since cost is a reasonable factor in planning a multi-month course.

For anything beyond the general picture (whether to slow your titration, how to handle a missed injection, or what your specific response at 1.0 mg means for your plan) those are questions for your prescriber. Our clinical team reviews every consultation individually, and repeat prescriptions at nume are each assessed fresh before any further supply is issued. If you haven't started yet and want to understand whether Wegovy is appropriate for you, the right first step is a free consultation with our prescribers.